Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 13/20 | 0.65 |
| ▸ | HTR3A | P46098 | 5/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.43 |
| ▸ | HTR3B | O95264 | 1/20 | 0.43 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.43 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.43 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.43 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL843821 | 1.00 | CHRNA7 (0.65) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL843982 | 0.95 | CHRNA7 (0.58) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL843075 | 0.83 | CHRNA7 (0.72) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL842630 | 0.83 | CHRNA7 (0.72) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL843074 | 0.83 | CHRNA7 (0.72) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL843591 | 0.83 | CHRNA7 (0.58) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL6007105 | 0.81 | CHRNA7 (0.65) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL6480387 | 0.81 | CHRNA7 (0.66) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL6480392 | 0.81 | CHRNA7 (0.66) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 | |
| SCHEMBL6006363 | 0.81 | CHRNA7 (0.65) | CHRNA7HTR3AHTR3EHTR3BCHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | claimed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | claimed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | claimed |
| EP-1432707-B1 | AZABICYCLIC-SUBSTITUTED FUSED-HETEROARYL COMPOUNDS FOR THE TREATMENT OF DISEASE | PHARMACIA & UPJOHN CO LLC (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-1831683-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | Pfizer Products Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | PFIZER INC | 2006-06-29 | — | — | US | disclosed |
| WO-2006067611-A1 | METHODS OF MODULATING THE ACTIVITIES OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTOR | PFIZER PRODUCTS INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC | 2005-10-20 | — | — | US | disclosed |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | PFIZER INC. | 2005-10-06 | — | — | US | disclosed |
| US-6911543-B2 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PFIZER INC. (US) | 2005-06-28 | — | — | US | disclosed |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234092-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | CHRNA7 5/4885HTR3A 783/4885HTR3E 1519/4885 |
| US-20030153595-A1 | Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease | MALT1, TPMT, ABCB1 | CHRNA7 1401/4885HTR3A 2224/4885HTR3E 3192/4885 |
| US-20050222196-A1 | Azabicyclic-substituted fused heteroaryl compounds for the treatment of disease | UGT2B7, CYP3A7, UGT1A7 | CHRNA7 5/4885HTR3A 783/4885HTR3E 1519/4885 |
| US-20060142349-A1 | Methods of modulating the activities of alpha-7 nicotinic acetylcholine receptor | CHRNA7, CHRNA5, CHRNA4 | CHRNA7 1/4885HTR3A 238/4885HTR3E 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.